Pure Global

Cross Linking for Treatment of Corneal Infection - Trial NCT00912509

Access comprehensive clinical trial information for NCT00912509 through Pure Global AI's free database. This phase not specified trial is sponsored by Price Vision Group and is currently Terminated. The study focuses on Infectious Keratitis. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT00912509
Terminated
drug
Trial Details
ClinicalTrials.gov • NCT00912509
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Cross Linking for Treatment of Corneal Infection
A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis

Study Focus

Infectious Keratitis

riboflavin

Interventional

drug

Sponsor & Location

Price Vision Group

Indianapolis, United States of America

Timeline & Enrollment

N/A

May 01, 2009

Jun 01, 2013

30 participants

Primary Outcome

Time to Re-epithelialization

Summary

This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal
 cross linking system to treat corneal infections.

ICD-10 Classifications

Keratitis
Keratitis, unspecified
Other keratitis
Herpesviral keratitis and keratoconjunctivitis
Keratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere

Data Source

ClinicalTrials.gov

NCT00912509

Non-Device Trial